Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desa Lilic

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|February 10, 2015
Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutationEleanor Higgins, Tariq Al Shehri, Maeve A McAleer, et al.
Journal of Clinical Immunology|July 29, 2018
Double Trouble? CMC with a Mutation in both AIRE and STAT1Huda Al Dhanhani, Tariq Al Shehri, Desa Lilic, et al.
Infection and Immunity|September 23, 2003
Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasisDesa Lilic, Ian Gravenor, Neil Robson, et al.
Autoimmunity|February 26, 2016
AIRE is not essential for the induction of human tolerogenic dendritic cellsKatherine L Crossland, Mario Abinun, Peter D Arkwright, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2010
Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophyWan-Fai Ng, Alexei von Delwig, Andrew J Carmichael, et al.
Journal of Clinical Immunology|September 13, 2019
Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to RuxolitinibTariq Al Shehri, Kimberly Gilmour, Florian Gothe, et al.
European Journal of Immunology|August 11, 2015
Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)Jie Zheng, Frank L van de Veerdonk, Katherine L Crossland, et al.
Plos One|December 24, 2011
STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasisSanne P Smeekens, Theo S Plantinga, Frank L van de Veerdonk, et al.
The New England Journal of Medicine|July 1, 2011
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasisFrank L van de Veerdonk, Theo S Plantinga, Alexander Hoischen, et al.
The Journal of Clinical Endocrinology and Metabolism|August 30, 2008
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type IAntonella Meloni, Maria Furcas, Filomena Cetani, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|February 10, 2015
Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutationEleanor Higgins, Tariq Al Shehri, Maeve A McAleer, et al.
Journal of Clinical Immunology|July 29, 2018
Double Trouble? CMC with a Mutation in both AIRE and STAT1Huda Al Dhanhani, Tariq Al Shehri, Desa Lilic, et al.
Infection and Immunity|September 23, 2003
Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasisDesa Lilic, Ian Gravenor, Neil Robson, et al.
Autoimmunity|February 26, 2016
AIRE is not essential for the induction of human tolerogenic dendritic cellsKatherine L Crossland, Mario Abinun, Peter D Arkwright, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2010
Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophyWan-Fai Ng, Alexei von Delwig, Andrew J Carmichael, et al.
Journal of Clinical Immunology|September 13, 2019
Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to RuxolitinibTariq Al Shehri, Kimberly Gilmour, Florian Gothe, et al.
European Journal of Immunology|August 11, 2015
Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)Jie Zheng, Frank L van de Veerdonk, Katherine L Crossland, et al.
Plos One|December 24, 2011
STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasisSanne P Smeekens, Theo S Plantinga, Frank L van de Veerdonk, et al.
The New England Journal of Medicine|July 1, 2011
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasisFrank L van de Veerdonk, Theo S Plantinga, Alexander Hoischen, et al.
The Journal of Clinical Endocrinology and Metabolism|August 30, 2008
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type IAntonella Meloni, Maria Furcas, Filomena Cetani, et al.
Pageof 3